Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROTOR registry of radium-223 outcomes in symptomatic metastatic castration-resistant prostate cancer
NL-OMON19873Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label trial of radium-223 dichloride in prostate cancer (PCa) (2 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoints: Effect on symptomatic skeletal events and Analgesic use and pain outcome. Started Apr 2015; status: recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON19873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19873.